Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs Carvana Co (CVNA) Price & Performance

Abbott LaboratoriesTrade
Carvana CoTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs Carvana Co — how do they compare? Abbott Laboratories trades at $110.7 (market cap $187.95B), while Carvana Co trades at $71.01 (market cap $79.17B). The key difference: Abbott Laboratories is far larger — about 2.4× Carvana Co's market cap, and Abbott Laboratories pays a 2.32% dividend while Carvana Co pays none. Which is the better fit depends on your goals.

ABTCVNA
Market Cap
$187.95B$79.17B
Sector
HealthConsumer Cyclical
52-Week High
$136.62$95.69
52-Week Low
$82.57$56.27
Enterprise Value
$214.96B$81.65B
Dividend Yield
2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

Carvana Co

Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.

Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About Carvana Co

Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.

Read more on CVNA